Nanoscale Immune Activator for Enhancing CD8+ T Cell Infiltration in Hepatocellular Carcinoma
ACS Nano · 10.11.2026 · 20 (44) · 29435-29455
DOI: 10.1021/acsnano.6c05553 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 24.10.2026. Verfasst von Deyu Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, General Hospital of Northern Theater Command, 110840Shenyang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, CD8-Positive T-Lymphocytes, Nanoparticles. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, National Natural Science Foundation of China (NSFC), General Hospital of the Northern Theater Command of the People's Liberation Army.
Abstract (Originalsprache)
The infiltration of CD8+ T cells into the hepatocellular carcinoma (HCC) microenvironment is a well-established determinant of immunotherapy efficacy and patient prognosis. However, the regulatory mechanisms governing this process and the therapeutic strategies capable of modulating it remain largely unexplored. Here, we identify HCC-IN-247 as a candidate compound that enhances IFNβ-driven CD8+ T cell infiltration both in vitro and in vivo. Mechanistic investigations reveal that the long noncoding RNA LINC02084 directly interacts with the transcription factor GLIS1 and facilitates its recruitment to the IFNβ promoter. HCC-IN-247 was identified through screening to target the LINC02084-GLIS1 binding interface, thereby stabilizing this RNA–protein complex. Stabilization of the complex significantly enhances IFNβ transcription, which in turn upregulates CXCL10 and CXCL11 expression and promotes CD8+ T cell infiltration. Furthermore, this study engineered a nanoparticle-based delivery system, designated Lip@RA@BSA-PD-L1/IN-247, for the codelivery of HCC-IN-247 and the anti-PD-L1 antibody atezolizumab in HCC treatment. These nanoparticles exhibited robust tumor-specific accumulation and elicited potent synergistic antitumor activity against HCC in mice. Collectively, our findings establish HCC-IN-247 as an activator of the tumor immune microenvironment and provide a preclinical basis for a combined immunotherapeutic approach to HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, General Hospital of Northern Theater Command, 110840Shenyang, China.
- Department of Surgery, The 965th Hospital of Chinese PLA, 132000Jilin, China.
- Department of Pathology, General Hospital of Northern Theater Command, Shenyang110840, China.
- State Key Laboratory of National Security Specially Needed Medicines, 100039Beijing, China.
- Department of Medical Oncology, Air Force Medical Center, The Fourth Military Medical University, 100142Beijing, China.
ORCID-Profile: Pengyun Li, Xingshun Qi
Förderung
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China (NSFC)
- General Hospital of the Northern Theater Command of the People's Liberation Army
Zitieren
APA
Zhang, D., Peng, D., Wang, X., Gao, Y., Liu, Z., Yang, R., Wei, T., Li, C., Gao, C., Jiang, Z., Miao, H., Li, P., & Qi, X. (2026). Nanoscale Immune Activator for Enhancing CD8+ T Cell Infiltration in Hepatocellular Carcinoma. ACS Nano, 20(44), 29435-29455. https://doi.org/10.1021/acsnano.6c05553
Vancouver
Zhang D, Peng D, Wang X, Gao Y, Liu Z, Yang R, et al. Nanoscale Immune Activator for Enhancing CD8+ T Cell Infiltration in Hepatocellular Carcinoma. ACS Nano. 2026;20(44):29435-29455. doi:10.1021/acsnano.6c05553
BibTeX
@article{Zhang2026,
author = {Zhang, Deyu and Peng, Dongxin and Wang, Xin and Gao, Yuting and Liu, Zhuang and Yang, Rui and Wei, Ting and Li, Chengkun and Gao, Cong and Jiang, Zhixin and Miao, Hongkun and Li, Pengyun and Qi, Xingshun},
title = {Nanoscale Immune Activator for Enhancing CD8+ T Cell Infiltration in Hepatocellular Carcinoma},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {44},
pages = {29435--29455},
doi = {10.1021/acsnano.6c05553}
}
EUVIMED